ICBio-Initiative
Bengaluru, India· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
An Indian full-service CRO providing cost-effective, end-to-end clinical research solutions, including BA/BE studies and bioanalytical services, for global pharma and biotech clients.
Broad Service Provider - No Specific Therapeutic Focus
Technology Platform
Integrated clinical and bioanalytical service platform featuring state-of-the-art LC-MS/MS and ICP-MS instrumentation, a 100+ bed clinical unit, and a NABL-accredited central laboratory for end-to-end clinical research support.
Opportunities
Growth opportunities include expanding its service footprint in biosimilar and complex generic drug development, capitalizing on its regulatory approvals in emerging markets, and leveraging its extensive volunteer and patient database for faster trial recruitment.
Risk Factors
Key risks include high competition in the Indian CRO sector, regulatory and compliance risks across multiple jurisdictions, potential pricing pressure from clients, and dependence on the cyclical nature of global pharmaceutical R&D spending.
Competitive Landscape
Competes with other Indian CROs (e.g., Syngene, Lambda Therapeutic) and global CROs on cost and quality; differentiates through a strong track record in BA/BE studies, multiple international regulatory approvals, and an integrated, in-house clinical and bioanalytical infrastructure.